Trial Profile
A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Deferiprone (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms SKY
- Sponsors ApoPharma
- 14 Nov 2019 Status changed from active, no longer recruiting to completed.
- 16 Oct 2019 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 31 Oct 2018 Planned End Date changed from 1 Oct 2019 to 1 Dec 2019.